Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., an orphan-drug accelerator that identifies and de-risks programs with therapeutic and commercial potential, Vtesse is working collaboratively with the NIH to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. Vtesse is led by a highly experienced management team that has been involved in the development of more than 20 approved drugs and vaccines. Its experienced consortium of investors, led by New Enterprise Associates, has committed initial funding that is expected to bring this compound through pivotal clinical trials.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/07/15 | $25,000,000 | Series A |
Alexandria Real Estate Equities Bay City Capital Lundbeckfond Ventures Pfizer Strategic Investments Group | undisclosed |
| 07/25/16 | $17,000,000 | Series A Extension |
Alexandria Real Estate Equities Bay City Capital Lundbeckfond Ventures Pfizer Venture Investments | undisclosed |
